{
    "type": "ETP",
    "ucits": false,
    "replication_method": "synthetic",
    "leverage": true,
    "derivatives": true,
    "swaps": false,
    "inverse": false,
    "complex_factors": [
        "Leverage",
        "Daily rebalancing compounding effect",
        "Synthetic exposure to index",
        "High risk rating (7/7)",
        "Collateralised structure",
        "No capital protection"
    ],
    "classification": "complex",
    "supporting_data": "The product is a Collateralised Exchange Traded Security (ETP) providing 5x leveraged exposure to the daily performance of the Solactive Magnificent 7 Index. It explicitly states a 5 times leverage ratio, which is a key complexity trigger. The product uses a margin account holding the underlying assets and collateral assets, indicating a synthetic replication method rather than physical replication. The KIID warns about the compounding effect due to daily leverage rebalancing, which can cause returns to deviate significantly from 5x the underlying index over longer holding periods. The risk indicator is at the highest level 7/7, confirming very high risk and complexity. The product is not UCITS compliant and is intended for sophisticated investors with a very short holding period (recommended 1 day). There is no capital protection, and the product may be difficult to understand for retail investors. Although the document does not explicitly mention swaps or total return swaps, the collateralised structure and margin account usage imply synthetic exposure and derivative usage inherent in leveraged ETPs. The PRIIPs KID also includes a comprehension warning, reinforcing the complexity classification. The product\u2019s costs include daily management fees and transaction costs, but no performance fees. The absence of physical replication and the presence of leverage and synthetic exposure are the main drivers of complexity under MiFID II. Therefore, the classification is complex."
}